Starting from the discovery of anti-SRP antibodies and the subsequent analysis of clinical features and pathological characteristics of anti-SRP polymyositis (13–15), IMNM was proposed as a new subgroup of IIMs at the 119th EMNC, based on pathological criteria. This evidence concerns the gene UCN2 and polymyositis.